Categories: NeurologyNews

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on New ‘Dendranib’ Nanomedicine Candidate at the 16th International Society of Neuroimmunology Congress (ISNI)

  • Data will showcase anti-inflammatory and immunomodulatory effects of ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, in a mouse model of multiple sclerosis 

REDWOOD CITY, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a new class of nanomedicine therapeutics, today announced a poster presentation of preclinical data on ASH41020, its new ‘dendranib’ nanomedicine candidate, at the International Society of Neuroimmunology Congress (ISNI) being held August 21 – 24, 2023 in Québec City, Canada.

The presentation will showcase the anti-inflammatory and immunomodulatory effects of ASH41020 through its selective targeting of activated microglia and macrophages in regions of inflammation in a mouse model of Multiple Sclerosis (MS).

The details of the poster presentation are as follows:

Poster Title: ASH41020, A Novel Hydroxyl Dendrimer CSF1R Tyrosine Kinase Inhibitor ‘Dendranib’ Nanomedicine, Polarizes Macrophages Toward an Anti-Inflammatory Phenotype and Improves Disease Severity in a Mouse Model of Multiple Sclerosis
Session Title: Inflammation in Neurodegenerative Diseases
Abstract Presentation Number: 259
Presenter: Jeffrey L. Cleland, Ph.D., Chairman, President and CEO, Ashvattha Therapeutics
Date/Time: Monday August 21, 2023, 4:15 p.m. – 6:15 p.m ET 
Location: Centré Des Congrés Québec 

About Ashvattha Therapeutics

Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells only in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation. For more information, visit: www.avttx.com 

Media Contact
Sky Striar
LifeSci Communications
617-797-6672
sstriar@lifescicomms.com

Staff

Recent Posts

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO),…

15 hours ago

Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly

Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology…

15 hours ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX,…

15 hours ago

Numinus Clarifies Disclosures

Vancouver, British Columbia--(Newsfile Corp. - June 7, 2024) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX:…

1 day ago

Woodfords Family Services Media Notice of Information Security Incident

WESTBROOK, ME / ACCESSWIRE / June 7, 2024 / What Happened?We discovered unauthorized access on…

1 day ago

cbdMD, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Charlotte, North Carolina--(Newsfile Corp. - June 7, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

1 day ago